AlphAIAlphAI — Financial news for AI agents
tradingview.com

Regeneron Pharmaceuticals Director Sold Shares Worth Over $7.2M

Regeneron Pharmaceuticals director Huda Y. Zoghbi sold 7,439 shares for $7.22M at prices of $970.42 and $971.06 per share, according to an SEC filing. She now directly owns 1,703 shares.

Original reporting
tradingview.com
Published Nov 5, 2026, 9:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 10:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Regeneron Pharmaceuticals Director Sold Shares Worth Over $7.2M — source image
Source · tradingview.com
Decision brief

The 30-second read

Low
01

Why it matters

The $7.2M sale is a material insider transaction that could influence short‑term price dynamics.

02

Market read

Insider sales of this size are noteworthy for traders monitoring biotech stocks for short‑term pressure.

03

What to watch

Potential upcoming clinical data releases or partnership news could offset sell pressure.

Relevance 6/10Novelty 5/10Timing: today

Background

Regeneron Pharmaceuticals disclosed a Form 4 filing showing a director's share sale.

Market effects

Sector

May prompt scrutiny of other Regeneron insiders and biotech insider activity.

Regional

Limited to US biotech investors; no broader regional effect.

Global

Minimal; only affects Regeneron shareholders.

Counterpoint

What could challenge this read

The sale could be a routine liquidity move, not a negative signal; the stock may remain stable.

Key entities

  • Company
    Regeneron Pharmaceuticals

    US‑listed biotech (ticker RGEN) whose director sold shares.

  • Individual
    Huda Y. Zoghbi

    Director of Regeneron who executed the share sale.

Read at source← All news

Related articles

$LLYHighAI 8/10

Eli Lilly, Regeneron Lead Weight-Loss ETF THNR Higher

Eli Lilly (LLY) and Regeneron (REGN) led gains in the VettaFi Weight Loss Drug & Treatment Index, which rose 3.28% in October. Lilly's Q3 revenue of $24.4B beat estimates, and it raised its 2026 forecast. Regeneron's revenue jumped 36%. AstraZeneca (AZN) and Roche also contributed to the index's gains, while CSPC Pharmaceutical Group and Structure Therapeutics fell.

etfdb.com
HighAI 8/10

Why is Regeneron Pharmaceuticals stock surging today?

Regeneron Pharmaceuticals' stock rose 4.0% to a 52-week high of $972.06 after reporting Q3 2026 earnings of $20.07 per share, up 70% Y/Y, and revenue of $5.116B, up 36% Y/Y. Multiple analysts raised price targets, with BofA Securities at $1,030 and Canaccord Genuity at $1,175. Positive Phase 3 trial data for Libtayo also supported the stock.

investing.com
$REGNMedAI 9/10

Regeneron Stock Jumps 13% to 52-Week High as Sanofi Dupixent Windfall Powers a Blockbuster Third Quarter

Regeneron (REGN) shares rose 13.33% to a 52-week high after reporting Q3 earnings and revenue above expectations, driven by its partnership with Sanofi on Dupixent. Adjusted earnings were $20.07 per share, up 70% YoY, and revenue rose 36% to $5.12 billion. Collaboration revenue from Sanofi reached $2.7 billion, up 68% YoY. The company also expanded its alliance with Sanofi, with a $1 billion upfront payment expected in Q4.

ibtimes.com.au